Biolog-id Branches out to the United States with a New Operational Center in Atlanta
Biolog-id, a world leader in connected health solutions, today announced the establishment of its U.S. operational center in Atlanta. This new site will enable Biolog-id to continue the growth of its presence in North America and offer its business solutions in the biggest health market in the world.
Biolog-id LLC’s offices are located in Alpharetta, 15 minutes north of Atlanta, Georgia. Pierre Parent, President of Biolog-id, has named Amit Mayer as the General Manager of the subsidiary.
Amit Mayer is an experienced manager with a variety of experience in the health, innovation, marketing and education domains. As an entrepreneur, consultant, teacher and businessman, Amit has worked for high-profile businesses and organizations throughout the world and is particularly interested in the healthcare sector. He has been based in Atlanta for the last 5 years.
“Biolog-id has developed unique expertise in connected health solutions and has created a ground-breaking innovation which enables the reliable tracking of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, and chemotherapy products), and ensures their safe administration to patients. By establishing a permanent presence in the US, Biolog-id aims to offer local clients quality support for its product offerings in America. This operational center will manage sales, sales support, operations and R&D. “Biolog-id is poised to establish itself in the US market and we are convinced Amit is the right person to make this a success”, says Pierre Parent.
“Biolog-id’s solutions are based on the Internet of Things (IoT), which improves the quality and safety of medical procedures and patient care by ensuring that the right product is administered to the right patient, and allowing healthcare professionals to devote more time to patient”, adds Amit Mayer. “They can be entirely integrated into existing work processes and provide significant financial savings by reducing product loss and optimizing the supply chain (reducing stock, remote management with no manual handling, etc.). In addition, Biolog-id’s solutions also help improve working conditions for healthcare professionals by relieving them of time-consuming administrative and logistical tasks. This transatlantic site is testament to our aim to make use of all our synergies to provide the North-American market with a one-of-a-kind service offering. By forming a team that is focused on adapting solutions to the specific features of blood transfusion centers, hospital blood banks and pharmacies responsible for injectable products, Biolog-id aims to provide ad hoc solutions with significant added value, enabling our rapid growth in North America.”
Biolog-id was founded in 2005 based on a pioneering concept: using RFID technology to identify, track and manage sensitive health products (red blood cells, plasma, platelets, chemotherapy products). This ground-breaking innovation enabled the development of a totally unique product: the “Biolog solution” and its intellectual property rights, currently amounting to 100 or so international patents.
The company’s corporate office is located in Paris and its manufacturing and product and customer support facility is situated in Bernay in the Normandie region of France. It currently employs approximately 80 people and is continuing its recruitment plan both in France and abroad. www.biolog-id.fr
Amit Mayer, +1 404 953 3169
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Valence Group Advises INEOS on Its Sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH24.4.2019 13:54:00 CEST | Pressemelding
The Valence Group Advises INEOS Enterprises, a division of INEOS (“INEOS”), on its sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH. The Valence Group acted as financial advisor to INEOS Enterprises on its announced sale of INEOS Melamines & Paraform to Prefere Resins Holding GmbH. The agreement covers sites in USA, Germany and Indonesia. INEOS Paraform is Europe’s second largest producer of Paraformaldehyde. INEOS Melamines is a world leader in the supply of melamine resins into coatings, paper, textile, tyre, rubber, and decorative laminates industries. Financial terms of the transaction were not disclosed. About The Valence Group The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategy consulting within the chemicals and materials ind
Centreon EMS Removes IT Monitoring Blind Spots between Hybrid, Multi-Cloud and Physical Networks24.4.2019 13:19:00 CEST | Pressemelding
Centreon, a trusted provider of enterprise monitoring solutions for converging and hybrid IT infrastructures, today rolled out a new release of Centreon EMS, its flagship, end-to-end IT monitoring platform. The new release provides ITOps with holistic and contextual insights, through the integrations needed for today’s distributed, on-premise and multi-cloud - public, private and container - environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005610/en/ Credits: GIF file of Centreon GeoViews. Centreon’s EMS 19.04 release offers ITOps managing a host of legacy assets but now contending with increased cloud workloads and growing networks of connected objects, the integrated visibility needed to ensure end-to-end performance across diverse IT environments. This expanded functionality reduces costs and complexity, aggregating data from across the entire IT infrastructure into a single, holistic view of the various
Neustar Research Shows Large Attacks Growing as Multi-Vector Exploits Increasingly Become the Norm24.4.2019 13:00:00 CEST | Pressemelding
Neustar, Inc., a trusted, neutral provider of real-time information services, today released its Q1, 2019 Cyber Threats and Trends report which highlights new areas of growth in Distributed Denial of Service (DDoS) attacks over the past year. The report affirms that DDoS attacks continue to be an effective means to distract and confuse security teams while inflicting serious damage to brands. The report reveals that while volumetric attacks over 50Gbps remain a relatively small segment of the overall threat picture at only 12% of attacks, their frequency has grown enormously when compared to the same period in 2018. The latest attacks morph over the course of the attack using a variety of ports and protocols to locate and exploit vulnerabilities. In Q1, 2019, over 77% of attacks used two or more vectors. In particular, the trend of targeting subnets and classless inter-domain routing (CIDR) blocks to slow or stop network traffic across the internet is a disruptive DDoS threat, identifi
Seoul Semiconductor Continues Enforcement against Infringement of Its LED Driver Patents24.4.2019 13:00:00 CEST | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it has filed another patent infringement lawsuit for infringement of its LED driver patents, this time against SATCO Products, Inc. (“SATCO”). In its complaint, Seoul asserts that SATCO is selling various LED lighting products that infringe “eleven” (11) of Seoul’s patents covering LED driver technology, including U.S. Patent 7,081,722, U.S. Patent 9,807,828; U.S. Patent 8,513,899; and U.S. Patent 8,716,946. The asserted LED driver patents are widely used in replacement bulbs in the form of incandescent or fluorescent lamps, wall-mount lights, and ceiling lights. The patented technology covers products with a linear driver for directly operating LEDs under household voltage, a step operation driver for generating flicker-free lights, as well as a dimmable driver for realizing smart lighting. Seoul has successfully enforced its LED driver patents in several
Immersion Signs Agreement With TDK Electronics Bringing Haptics Design and Marketing to PowerHap Piezo Actuators24.4.2019 12:30:00 CEST | Pressemelding
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced that it has signed an agreement with TDK Corp. (TSE:6762) subsidiary TDK Electronics for the design and marketing of haptic feedback for TDK PowerHap™ piezo actuators. Under the agreement, Immersion will include TDK’s actuators in reference designs for automotive, industrial and other markets. Immersion will also certify the components for use with its software products. This will enable TDK’s customers in a wide variety of markets to rapidly implement cutting-edge haptic solutions with its high-performance actuators. With 25 years in the field of touch technology, Immersion brings together the art of design and the precise science behind haptic feedback in actuators and ICs. The company connects the haptic ecosystem through the certification of haptic components, helping partners like TDK and their customers maintain consistency and high-fidelity haptic experiences across de
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities24.4.2019 12:30:00 CEST | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta® (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005257/en/ “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalized CAR T and TCR cell therapies for people with cancer. As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essentia